Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.
EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging
Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.
EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis
Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.
EP. 3: Treatment Approaches in AL Amyloidosis
Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.
EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement
Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.
EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial
Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.
EP. 6: Birtamimab Safety Profile in the VITAL Study
Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.
EP. 7: Adverse Event Management in AL Amyloidosis
Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.
EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment
Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.
EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches
Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.
EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis
Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer